Extravasation GuideTissue injury risk of antineoplastic extravasation

Vindesine

Vindesina

Risk class

Vesicant

If it extravasates

Antidote

Hyaluronidase

Compress

Warm

References

Risk class: VesicantESMO-EONS 2012 (Table 1, p. vii167); JSCN/JSMO/JASPO 2024 (Table 2)

Antidote: hyaluronidaseESMO-EONS 2012 (Table 5, p. vii173)

Compress: warmESMO-EONS 2012 (Fig. 1, p. vii170)

Not classified in: ONS/ASCO 2025

Details by guideline

Risk class in extravasation

ESMO-EONS 2012Vesicant
Vesicants › Non-DNA-binding compounds › Vinka alkaloids
Table 1, p. vii167
JSCN/JSMO/JASPO 2024Vesicant
Table 2

Not classified in: ONS/ASCO 2025

Specific antidote

ESMO-EONS 2012Hyaluronidase
Strength/level: V-CVinka alkaloids
Table 5, p. vii173

Compress

ESMO-EONS 2012Warm compress
"Disperse and dilute"Vinka alkaloids; Taxanes; Platin salts
Figure 1, p. vii170

Brand names (ANVISA, Brazil) · DCB (Brazil)

DCB (Brazil)vindesina (nº 9152)

General recommendations of the guidelines

ONS/ASCO 2025Recommendation 1 · Strong; very low
Use antidotes, when one exists, for vesicants and irritants with vesicant properties, rather than no antidote.
Table 3, p. 388
ONS/ASCO 2025Recommendation 3 · Conditional; very low
Thermal compress (cold or warm depending on the agent) rather than no compress.
Table 3, p. 388
ONS/ASCO 2025Recommendation 4 · Conditional; very low
Compress for more than 24 hours rather than 24 hours or less.
Table 3, p. 388
ONS/ASCO 2025Recommendation 5 · Conditional; very low
Central line extravasation: surgical referral or escalation of care in addition to conservative management.
Table 3, p. 388
JSCN/JSMO/JASPO 2024CQ10a · Recommend (weak)
Cold compression (weak recommendation).
Table 1, CQ10a
JSCN/JSMO/JASPO 2024CQ10b · Not recommend (weak); D
Non-use of warm compresses (weak recommendation).
Table 1, CQ10b

Search another drug